Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1410 in advanced solid tumors or lymphoma
NCT05357651Phase 1Recruiting
- Sponsor
- L&L Biopharma Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of LB1410 in solid tumor (advanced stage), lymphoma, non-small cell lung cancer (NSCLC) and 8 more (3 arms), sponsored by L&L Biopharma Co., Ltd. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Incidence and severity of serious adverse events and 2 more. Started Aug 2022; status: recruiting.
02
Drugs
LB1410
03
Conditions
solid tumor (advanced stage)lymphomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05357651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357651.